Opportunity

Despite years of research and clinical trials, many neurological and neuropsychiatric disorders are still poorly understood. While current therapies may treat symptoms, the underlying pathologies remain unaddressed. New, effective treatments will have significant societal and financial benefits.

An estimated 5 million Americans over age 65 have Alzheimer’s disease, a number that is projected to reach 13.8 million by 2050. Alzheimer’s disease is the sixth leading cause of death. Current FDA-approved drugs merely ameliorate or delay some of the symptoms displayed by patients and are efficacious only for about 6 to 12 months.

Approximately 60,000 Americans are diagnosed with Parkinson’s disease each year. Medications and surgery are available to treat the symptoms of the disease but there is currently no cure.

Psoriasis is the most common autoimmune disease in the United States, affecting as many as 7.5 million Americans. Topical and injectable medications are available to treat the symptoms of the disease but do not effect a cure.

While there is a range of treatments available for depression, these take weeks to achieve onset of action and are not effective for up to 40% of the patient population.

70 million US citizens suffer from chronic sleep disturbances. There are sleep aids that promote the onset of sleep, but no medications that promote a night of consolidated sleep.